Ranesan

Prevention & treatment of haemorrhages due to general or local fibrinolysis in adults & childn ≥1 yr, including haemorrhage caused by general or local fibrinolysis eg, menorrhagia & metrorrhagia; GI bleeding; haemorrhagic urinary disorders (further to prostate surgery or surgical procedures affecting the urinary tract); ENT surgery (adenoidectomy, tonsillectomy, dental extractions); gynaecological surgery or disorders of obstet origin; thoracic & abdominal surgery & other major surgical intervention (eg, CV surgery). Management of haemorrhage due to the administration of a fibrinolytic agent.

Slow IV inj Adult Local fibrinolysis 0.5-1 g bid-tid. General fibrinolysis 1 g every 6-8 hr, equiv to 15 mg/kg. Childn ≥1 yr 20 mg/kg/day. Patient w/ renal impairment, serum creatinine 120-249 micromol/L 10 mg/kg every 12 hr, 250-500 micromol/L 10 mg/kg every 24 hr, >500 micromol/L 5 mg/kg every 24 hr.

Hypersensitivity. Acute venous or arterial thrombosis. Fibrinolytic conditions following consumption coagulopathy except in those w/ predominant activation of the fibrinolytic system w/ acute severe bleeding. History of convulsions. Intrathecal & intraventricular inj, intracerebral application (risk of cerebral oedema & convulsions). Severe renal impairment (risk of accumulation).

Do not administer by IM inj. Risk of urethral obstruction in case of haematuria from upper urinary tract. Consider risk factors of thromboembolic disease before use. Administer w/ care in patients receiving OCs. Only administer in patients w/ history of thromboembolic diseases or w/ increased incidence of thromboembolic events in family history if there is a strong medical indication & under strict medical supervision. Patients w/ disseminated intravascular coagulation should not be treated w/ tranexamic acid in most cases; if to be given, restrict use to patients in whom there is predominant activation of the fibrinolytic system w/ acute severe bleeding. Reported cases of convulsions. Pay attention to possible visual disturbances including visual impairment, blurred vision, impaired colour vision & discontinue treatment if necessary. Regular ophthalmologic exam are indicated w/ continuous long-term use. Contains Na metabisulfite that may cause allergic-type reactions including anaphylactic symptoms & life-threatening or less severe asthmatic episodes in certain susceptible patients. Patients w/ mild to moderate renal impairment. Women of childbearing potential have to use effective contraception during treatment. Not recommended during 1st trimester of pregnancy. Use throughout pregnancy only if expected benefit justifies potential risk. Breastfeeding is not recommended. Limited data on efficacy, posology & safety in childn ≥1 yr for current approved indications. Efficacy, posology & safety have not been fully established in childn undergoing cardiac surgery. Elderly w/ evidence of renal failure.

Diarrhoea, vomiting & nausea. Allergic dermatitis.

Simultaneous treatment w/ anticoagulants must take place under strict medical supervision. Use medicinal products that act on haemostasis w/ caution. Theoretical risk of increased thrombus-formation potential w/ oestrogens. Antifibrinolytic action of tranexamic acid may be antagonised w/ thrombolytic drugs.

Haemostatics

B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.

Rx